(IN BRIEF) GSK and Shionogi have agreed with Pfizer to restructure ViiV Healthcare’s shareholder base, with Shionogi replacing Pfizer’s 11.7 percent economic interest and increasing its stake to 21.7 percent, while GSK maintains a 78.3 percent majority holding. The transaction, … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biopharma partnership, cabotegravir, David Redfern, dolutegravir, GSK, HIV prevention, HIV treatment, integrase inhibitors, John Keller, long acting injectables, Pfizer, pharmaceutical industry, shareholder restructuring, Shionogi, strategic investment, ViiV Healthcare, ViiV Healthcare Ownership Streamlined with Expanded Shionogi Investment and GSK Majority
(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cabotegravir, CHINA, Chinese Approval, Deborah Waterhouse, GSK, HIV, injection, partnership, Pfizer, Rekambys, rilpivirine, Shionogi, sustainability, treatment, ViiV Healthcare, Vocabria
(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Apretude, Dovato, EACS 2023, GSK, HIV, Kimberly Smith, partnership, Pfizer, prevention, Rekambys, Rukobia, Shionogi, treatment, ViiV Healthcare, Vocabria
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?